ADNI GO
ADNI was extended in 2009 during the ADNI GO phase, which assessed the existing ADNI1 cohort along with 200 new participants with early mild cognitive impairment (EMCI). The objective of this phase was to examine biomarkers at an earlier stage of the disease. MR protocols were also adjusted in the ADNI GO phase.
Further Reading
ADNI2
In 2011, ADNI2 began with an additional $67 million in funding, assessing participants from the ADNI1/ADNI GO phases in addition to the following new participant groups: 150 elderly controls, 100 EMCI subjects, 150 late mild cognitive impairment (LMCI) subjects, and 150 mild AD patients. A new cohort, Significant Memory Concern (SMC), was also added in ADNI2 to address the gap between healthy controls and MCI; a key inclusion criteria is a self-reported significant memory concern from the participant. The study included 107 SMC subjects. A major addition to ADNI2 was the addition of amyloid PET with Florbetapir at all ADNI2 sites and on all ADNI2 and ADNI GO subjects.
Further Reading